Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC announces the appointment of biotechnology industry veteran Dennis Purcell as its new Chairman, succeeding Nicholas Nelson. Purcell, renowned for his leadership at Aisling Capital and expertise in healthcare investment, is set to steer the company’s strategic partnerships, starting with a collaboration with Awakn Life Sciences to develop treatments for mental health disorders like PTSD. In recognition of his new role, Purcell has been granted 45 million options under the company’s Long Term Incentive Plan.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
